Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status approved
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII 53AH36668S
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lymphatic disorder01.09.01.003--Not Available
Epigastric discomfort07.01.02.0040.000112%Not Available
Musculoskeletal discomfort15.03.04.0010.000246%Not Available
Organ failure08.01.03.0410.000112%Not Available
Oesophageal discomfort07.01.06.0300.000381%Not Available
Tumour necrosis24.04.02.013; 16.32.03.0090.000168%Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Transaminases increased13.03.04.036--Not Available
Hypoaesthesia oral07.05.05.003; 17.02.06.0210.000492%Not Available
Reflux gastritis07.08.02.0040.000437%Not Available
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000280%Not Available
Dysgraphia17.02.03.0060.000246%Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.0010.025945%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000929%Not Available
Early satiety14.03.01.010; 08.01.09.004; 07.01.06.0270.000246%Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.001041%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000302%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Neurological symptom17.02.05.0100.000168%Not Available
Appetite disorder19.09.01.002; 14.03.01.0040.000627%Not Available
Brain neoplasm17.20.01.003; 16.30.01.0030.000302%Not Available
Cardiac disorder02.11.01.003--Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.000246%Not Available
Embolism24.01.01.0090.000728%
Gastrointestinal motility disorder07.02.03.0010.000627%Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.000280%Not Available
Infestation11.09.01.001; 23.11.01.002--Not Available
Inflammation10.02.01.089; 08.01.05.0070.001914%Not Available
Limb discomfort15.03.04.0140.000414%Not Available
Malnutrition14.03.02.0040.000224%Not Available
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene